Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer

2009 ◽  
Vol 45 (12) ◽  
pp. 2110-2115 ◽  
Author(s):  
Suzanne Polinder ◽  
Els M.L. Verschuur ◽  
Peter D. Siersema ◽  
Ernst J. Kuipers ◽  
Ewout W. Steyerberg
Keyword(s):  
Oesophageal Cancer ◽  
Cost Comparison ◽  
Comparison Study

scholarly journals Foster children’s cognitive functioning: A follow-up comparison study at 8 years of age

2020 ◽  
Vol 118 ◽  
pp. 105342
Author(s):  
Heidi Jacobsen ◽  
Tore Wentzel-Larsen ◽  
Hans Bugge Bergsund
Keyword(s):  
Cognitive Functioning ◽  
Comparison Study

FA05.01: NON-ONCOLOGICAL PULMONARY MORTALITY IS ASSOCIATED WITH OESOPHAGECTOMY FOR CANCER

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 9-9
Author(s):  
Stefan Antonowicz ◽  
Sheraz Markar ◽  
Tom Wiggins ◽  
Hugh Mackenzie ◽  
Alan Askari ◽  
...  
Keyword(s):  
Oesophageal Cancer ◽  
Conflicts Of Interest ◽  
Cancer Recurrence ◽  
Disease Diagnosis ◽  
Mortality Data ◽  
Primary Cancer ◽  
Respiratory Mortality ◽  
Increased Risk

Abstract Background Improvements in oesophageal cancer care have meant ever more patients are being declared cured. Whether oesophagectomy itself causes long-term non-cancer mortality is not known. This study was conducted to assess the timing and frequency of non-cancer causes of death after oesophagectomy in the UK with a population-based survey. Methods Hospital Episode Statistics provides contemporaneous admission data for all inpatient National Health Service encounters since 2000. A linked database was constructed of all HES encounters with oesophagectomy treatment codes, with Office for National Statistics mortality data, which included cause and date of death. Minimum follow-up was to 5 years. Independent variables potentially predictive of cause of death were entered into logistic regression analyses. Results There were 7204 oesophagectomy patients for which linked mortality data was available. A total of 302 died within 90 days, and a further 5874 died of primary cancer recurrence. Of the remaining 908 non-index-cancer deaths, 238 (26.2%) died of respiratory causes, 210 (23.1%) died of other cancers, 158 (17.4%) died of cardiac diagnoses and 64 (7%) died of cerebrovascular diagnoses. Survival patterns for those dying of cardiac and primary cancer recurrence were similar, with 80% occurring within 2 years of surgery. Non-cancer respiratory mortality was a later occurrence, with 80% occurring by 6 years. A pre-operative pulmonary diagnosis was associated with pulmonary mortality (OR 2.66 95% C.I. 1.49–4.77, P < 0.001), and a pre-operative ischaemic heart disease diagnosis were associated with post-operative cardiac death (OR 2.28 95% C.I. 1.13–4.59, P = 0.021). Long-term respiratory mortality was associated with inpatient respiratory complications in the index encounter (OR 2.60 95% C.I. 1.36 to 4.98, P = 0.004). Comparison to mortality rates after colectomy for cancer revealed 2-fold increased risk of non-cancer pulmonary death after oesophagectomy. Conclusion Oesophagectomy may increase the risk of non-cancer respiratory death in oesophageal cancer survivorship, with implications for peri-operative pathways and follow-up programs. Further work is needed to test whether this is a consequence of reconstruction, peri-operative complications, or progression of pre-morbid diagnoses. Disclosure All authors have declared no conflicts of interest.

Infant day care as a treatment intervention: A follow-up comparison study

1977 ◽  
Vol 7 (3) ◽  
pp. 147-155
Author(s):  
Ruth C. Resch ◽  
Roy K. Lilleskov ◽  
Helen M. Schur ◽  
Thelma Mihalov
Keyword(s):  
Day Care ◽  
Treatment Intervention ◽  
Comparison Study

A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4530-4530 ◽  
Author(s):  
H. Carstens ◽  
M. Albertsson ◽  
S. Friesland ◽  
G. Adell ◽  
G. Frykholm ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Oesophageal Cancer ◽  
Primary Tumour ◽  
Radical Resection ◽  
Phase Iii ◽  
Surgery Group ◽  
Significant Difference ◽  
Resectable Esophageal ◽  
Resectable Esophageal Cancer

4530 Background: The aim of this study was to compare survival in a randomized phase III trial of chemoradiotherapy (CHRT) versus surgery alone for localized resectable oesophageal cancer. Methods: Between 2000 and 2004, 91 patients with oesophageal cancer were enrolled in a Scandinavian multicenter study. Patients with resectable oesophageal squamous cell carcinoma (50%) or adenocarcinoma (50%) were randomized to chemoradiotherapy (CHRT) or surgery alone. Chemotherapy (CHT) was given in 3 cycles with cisplatin 100 mg/m2, day 1 and 5-fluorouracil 750 mg/m2/24 hours, infusion day 1–5, every three weeks. After one induction chemotherapy course, radiotherapy including the primary tumour and defined locoregional lymph nodes, was given concomitant with the following CHT cycles, to a total dose of 64 Gy, in 32 fractions. Surgery was performed according to Ivor Lewis and lymph nodes resected with standard two-field technique. Results: At a median follow-up of 51.8 month’s 65 deaths are noted. In the chemoradiation group 50% of the patients accomplished therapy according to protocol, 40% were treated with modifications of the protocol and radical resection was performed 76% of the patients. Median survival was 12.8 months for chemoradiation and 15.8 months for the surgery group. There was no significant difference in 1-year survival 56% and 55% for CHRT and surgery, respectively. By two years, survival curves diverge and 2-years survival was 37% (CI 95%: 23–51%) for the CHRT group and 25% (CI 95%: 12–39%) for the surgery group. At four years, survival was 29% for CHRT versus 23% for surgery (CI 95% CHRT: 16–43%, CI 95% Surgery: 10–36%). Both treatments were well tolerated and no treatment related deaths were recorded in any of the treatment arms. Most deaths were due to tumor disease (66%) in both groups. Conclusions: No statistically significant differences between the treatment arms were seen and survival results are equal to earlier reported. Both treatment arms were well tolerated. No significant financial relationships to disclose.

scholarly journals PCV12: A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL IN THE TREATMENT OF HYPERTENSION IN EUROPE

2000 ◽  
Vol 3 (5) ◽  
pp. 314
Author(s):  
J Doyle ◽  
S Arikian ◽  
J Casciano ◽  
R Casciano ◽  
M Gonzalez ◽  
...  
Keyword(s):  
Cost Comparison ◽  
Comparison Study ◽  
Treatment Of Hypertension

PCN102 A Cost Comparison Study to Review Community Versus ACUTE Hospital Models of Nursing Care Delivered to Oncology Patients.

2021 ◽  
Vol 24 ◽  
pp. S38
Author(s):  
C. O'Mahony ◽  
K.D. Murphy ◽  
G.L. O'Brien ◽  
T. Hanan ◽  
L. Mullen ◽  
...  
Keyword(s):  
Nursing Care ◽  
Acute Hospital ◽  
Cost Comparison ◽  
Comparison Study ◽  
Oncology Patients
Sign in / Sign up

Export Citation Format

Share Document